tiprankstipranks
Trending News
More News >
Verve Therapeutics (VERV)
NASDAQ:VERV
US Market

Verve Therapeutics (VERV) Stock Forecast & Price Target

Compare
670 Followers
See the Price Targets and Ratings of:

VERV Analyst Ratings

Strong Buy
10Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Verve
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VERV Stock 12 Month Forecast

Average Price Target

$24.00
▲(318.85%Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Verve Therapeutics in the last 3 months. The average price target is $24.00 with a high forecast of $39.00 and a low forecast of $15.00. The average price target represents a 318.85% change from the last price of $5.73.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","40":"$40","12.25":"$12.25","21.5":"$21.5","30.75":"$30.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,12.25,21.5,30.75,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.5,8.076923076923077,10.653846153846153,13.230769230769232,15.807692307692308,18.384615384615387,20.961538461538463,23.53846153846154,26.115384615384617,28.692307692307693,31.26923076923077,33.84615384615385,36.42307692307693,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.5,6.923076923076923,8.346153846153847,9.76923076923077,11.192307692307693,12.615384615384617,14.038461538461538,15.461538461538462,16.884615384615387,18.307692307692307,19.730769230769234,21.153846153846153,22.576923076923077,{"y":24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.5,6.230769230769231,6.961538461538462,7.692307692307692,8.423076923076923,9.153846153846153,9.884615384615383,10.615384615384615,11.346153846153847,12.076923076923077,12.807692307692307,13.538461538461538,14.269230769230768,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.58,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.21,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.79,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.73,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$39.00Average Price Target$24.00Lowest Price Target$15.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on VERV
TipRanks AITipRanks
Not Ranked
TipRanks
$6
Hold
4.71%
Upside
Reiterated
06/06/25
Verve Therapeutics' stock is buoyed by strong technical momentum, despite challenges in financial performance and valuation. The company's robust balance sheet offers some financial stability, but its unprofitability and negative P/E ratio are significant concerns. Investors should be cautious of the high-risk profile due to the negative margins and volatile nature of the biotechnology sector.
Canaccord Genuity Analyst forecast on VERV
Whitney IjemCanaccord Genuity
Canaccord Genuity
$39
Buy
580.63%
Upside
Reiterated
05/23/25
Canaccord Genuity Reaffirms Their Buy Rating on Verve Therapeutics (VERV)
H.C. Wainwright Analyst forecast on VERV
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$25
Buy
336.30%
Upside
Reiterated
05/19/25
Verve Therapeutics (VERV) Gets a Buy from H.C. Wainwright
BMO Capital Analyst forecast on VERV
Kostas BiliourisBMO Capital
BMO Capital
$30$20
Buy
249.04%
Upside
Reiterated
05/15/25
Post 1Q: Strong '102 Data Set the Stage for Positive Data/Opt-in Updates in 2H
Guggenheim
$24
Buy
318.85%
Upside
Reiterated
05/14/25
Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), Verve Therapeutics (VERV)
William Blair Analyst forecast on VERV
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/14/25
William Blair Remains a Buy on Verve Therapeutics (VERV)
LifeSci Capital Analyst forecast on VERV
Cory Jubinville, PhDLifeSci Capital
LifeSci Capital
$25
Buy
336.30%
Upside
Reiterated
05/14/25
Buy Rating for Verve Therapeutics: Promising Phase 1 Data and Strong Financial Position
RBC Capital Analyst forecast on VERV
Luca IssiRBC Capital
RBC Capital
$15
Buy
161.78%
Upside
Reiterated
05/14/25
Analysts Are Bullish on Top Healthcare Stocks: Verve Therapeutics (VERV), Aardvark Therapeutics, Inc. (AARD)
Jefferies Analyst forecast on VERV
Eun YangJefferies
Jefferies
$28
Buy
388.66%
Upside
Reiterated
04/15/25
Jefferies reiterates Buy Rating on Verve Therapeutics (VERV)Jefferies analyst Eun Yang reiterated a Buy rating and $28.00 price target on Verve Therapeutics (NASDAQ: VERV)
J.P. Morgan Analyst forecast on VERV
Eric JosephJ.P. Morgan
J.P. Morgan
$19$16
Hold
179.23%
Upside
Reiterated
04/15/25
J.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)
Cantor Fitzgerald Analyst forecast on VERV
Rick BienkowskiCantor Fitzgerald
Cantor Fitzgerald
Buy
Upgraded
04/15/25
Verve Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldVerve Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Stifel Nicolaus Analyst forecast on VERV
Dae Gon HaStifel Nicolaus
Stifel Nicolaus
Buy
Reiterated
12/10/24
Stifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on VERV
TipRanks AITipRanks
Not Ranked
TipRanks
$6
Hold
4.71%
Upside
Reiterated
06/06/25
Verve Therapeutics' stock is buoyed by strong technical momentum, despite challenges in financial performance and valuation. The company's robust balance sheet offers some financial stability, but its unprofitability and negative P/E ratio are significant concerns. Investors should be cautious of the high-risk profile due to the negative margins and volatile nature of the biotechnology sector.
Canaccord Genuity Analyst forecast on VERV
Whitney IjemCanaccord Genuity
Canaccord Genuity
$39
Buy
580.63%
Upside
Reiterated
05/23/25
Canaccord Genuity Reaffirms Their Buy Rating on Verve Therapeutics (VERV)
H.C. Wainwright Analyst forecast on VERV
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$25
Buy
336.30%
Upside
Reiterated
05/19/25
Verve Therapeutics (VERV) Gets a Buy from H.C. Wainwright
BMO Capital Analyst forecast on VERV
Kostas BiliourisBMO Capital
BMO Capital
$30$20
Buy
249.04%
Upside
Reiterated
05/15/25
Post 1Q: Strong '102 Data Set the Stage for Positive Data/Opt-in Updates in 2H
Guggenheim
$24
Buy
318.85%
Upside
Reiterated
05/14/25
Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), Verve Therapeutics (VERV)
William Blair Analyst forecast on VERV
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/14/25
William Blair Remains a Buy on Verve Therapeutics (VERV)
LifeSci Capital Analyst forecast on VERV
Cory Jubinville, PhDLifeSci Capital
LifeSci Capital
$25
Buy
336.30%
Upside
Reiterated
05/14/25
Buy Rating for Verve Therapeutics: Promising Phase 1 Data and Strong Financial Position
RBC Capital Analyst forecast on VERV
Luca IssiRBC Capital
RBC Capital
$15
Buy
161.78%
Upside
Reiterated
05/14/25
Analysts Are Bullish on Top Healthcare Stocks: Verve Therapeutics (VERV), Aardvark Therapeutics, Inc. (AARD)
Jefferies Analyst forecast on VERV
Eun YangJefferies
Jefferies
$28
Buy
388.66%
Upside
Reiterated
04/15/25
Jefferies reiterates Buy Rating on Verve Therapeutics (VERV)Jefferies analyst Eun Yang reiterated a Buy rating and $28.00 price target on Verve Therapeutics (NASDAQ: VERV)
J.P. Morgan Analyst forecast on VERV
Eric JosephJ.P. Morgan
J.P. Morgan
$19$16
Hold
179.23%
Upside
Reiterated
04/15/25
J.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)
Cantor Fitzgerald Analyst forecast on VERV
Rick BienkowskiCantor Fitzgerald
Cantor Fitzgerald
Buy
Upgraded
04/15/25
Verve Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldVerve Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Stifel Nicolaus Analyst forecast on VERV
Dae Gon HaStifel Nicolaus
Stifel Nicolaus
Buy
Reiterated
12/10/24
Stifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Verve Therapeutics

1 Month
xxx
Success Rate
6/12 ratings generated profit
50%
Average Return
-3.28%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -3.28% per trade.
3 Months
xxx
Success Rate
6/12 ratings generated profit
50%
Average Return
-7.14%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -7.14% per trade.
1 Year
Kostas BiliourisBMO Capital
Success Rate
3/17 ratings generated profit
18%
Average Return
-31.42%
reiterated a buy rating 23 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 17.65% of your transactions generating a profit, with an average return of -31.42% per trade.
2 Years
xxx
Success Rate
2/12 ratings generated profit
17%
Average Return
-30.14%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -30.14% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VERV Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
6
8
13
18
18
Buy
1
3
3
5
4
Hold
1
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
11
16
24
23
In the current month, VERV has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VERV average Analyst price target in the past 3 months is 24.00.
Each month's total comprises the sum of three months' worth of ratings.

VERV Financial Forecast

VERV Earnings Forecast

Next quarter’s earnings estimate for VERV is -$0.67 with a range of -$0.82 to -$0.54. The previous quarter’s EPS was -$0.35. VERV beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year VERV has Outperformed its overall industry.
Next quarter’s earnings estimate for VERV is -$0.67 with a range of -$0.82 to -$0.54. The previous quarter’s EPS was -$0.35. VERV beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year VERV has Outperformed its overall industry.

VERV Sales Forecast

Next quarter’s sales forecast for VERV is $4.34M with a range of $0.00 to $13.08M. The previous quarter’s sales results were $32.98M. VERV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year VERV has Outperformed its overall industry.
Next quarter’s sales forecast for VERV is $4.34M with a range of $0.00 to $13.08M. The previous quarter’s sales results were $32.98M. VERV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year VERV has Outperformed its overall industry.

VERV Stock Forecast FAQ

What is VERV’s average 12-month price target, according to analysts?
Based on analyst ratings, Verve Therapeutics’s 12-month average price target is 24.00.
    What is VERV’s upside potential, based on the analysts’ average price target?
    Verve Therapeutics has 318.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VERV a Buy, Sell or Hold?
          Verve Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Verve Therapeutics’s price target?
            The average price target for Verve Therapeutics is 24.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $39.00 ,the lowest forecast is $15.00. The average price target represents 318.85% Increase from the current price of $5.73.
              What do analysts say about Verve Therapeutics?
              Verve Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of VERV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis